世界の線維筋性異形成治療市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Fibromuscular Dysplasia Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-107A12278
• 出版社/出版日：GlobalInfoResearch / 2021年7月
※2024年版があります。お問い合わせください。
• レポート形態：英文、PDF、128ページ
• 納品方法：Eメール（納期：2~3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥515,040 (USD3,480)	▷ お問い合わせ
Multi User	￥772,560 (USD5,220)	▷ お問い合わせ
Corporate User	￥1,030,080 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

当調査資料では、線維筋性異形成治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。線維筋性異形成治療の種類別市場規模（外科療法、投薬）、用途別市場規模（病院、クリニック、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。
・線維筋性異形成治療の市場概要
・企業情報（企業概要、製品概要、販売量、価格、売上）：Pfizer、Sanofi、Bayer、Merck、Novartis、Bristol-Myers Squibb、AstraZeneca、Allergan、Medtronic、BD、Smith & Nephew、Stryker、B. Braun Melsungen、Johnson & Johnson、Hill-Rom、Alkermes Pharma Ireland、Dainippon Sumitomo Pharma
・企業別市場シェア
・地域別市場分析2016年-2026年
・種類別分析2016年-2026年：外科療法、投薬
・用途別分析2016年-2026年：病院、クリニック、その他
・線維筋性異形成治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ
・線維筋性異形成治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア
・線維筋性異形成治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア
・線維筋性異形成治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン
・線維筋性異形成治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Fibromuscular Dysplasia Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Fibromuscular Dysplasia Treatment size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Fibromuscular Dysplasia Treatment market size is expected to grow at a CAGR of xx% for the next five years.

Market segmentation
Fibromuscular Dysplasia Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Surgery Therapy
Medication

Market segment by Application, can be divided into
Hospitals
Clinics
Others

Market segment by players, this report covers
Pfizer
Sanofi
Bayer
Merck
Novartis
Bristol-Myers Squibb
AstraZeneca
Allergan
Medtronic
BD
Smith & Nephew
Stryker
B. Braun Melsungen
Johnson & Johnson
Hill-Rom
Alkermes Pharma Ireland
Dainippon Sumitomo Pharma

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

レポート目次

1 Market Overview
1.1 Product Overview and Scope of Fibromuscular Dysplasia Treatment
1.2 Classification of Fibromuscular Dysplasia Treatment by Type
1.2.1 Overview: Global Fibromuscular Dysplasia Treatment Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Fibromuscular Dysplasia Treatment Revenue Market Share by Type in 2020
1.2.3 Surgery Therapy
1.2.4 Medication
1.3 Global Fibromuscular Dysplasia Treatment Market by Application
1.3.1 Overview: Global Fibromuscular Dysplasia Treatment Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Fibromuscular Dysplasia Treatment Market Size & Forecast
1.5 Global Fibromuscular Dysplasia Treatment Market Size and Forecast by Region
1.5.1 Global Fibromuscular Dysplasia Treatment Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Fibromuscular Dysplasia Treatment Market Size by Region, (2016-2021)
1.5.3 North America Fibromuscular Dysplasia Treatment Market Size and Prospect (2016-2026)
1.5.4 Europe Fibromuscular Dysplasia Treatment Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Fibromuscular Dysplasia Treatment Market Size and Prospect (2016-2026)
1.5.6 South America Fibromuscular Dysplasia Treatment Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Fibromuscular Dysplasia Treatment Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Fibromuscular Dysplasia Treatment Market Drivers
1.6.2 Fibromuscular Dysplasia Treatment Market Restraints
1.6.3 Fibromuscular Dysplasia Treatment Trends Analysis
2 Company Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Fibromuscular Dysplasia Treatment Product and Solutions
2.1.4 Pfizer Fibromuscular Dysplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Pfizer Recent Developments and Future Plans
2.2 Sanofi
2.2.1 Sanofi Details
2.2.2 Sanofi Major Business
2.2.3 Sanofi Fibromuscular Dysplasia Treatment Product and Solutions
2.2.4 Sanofi Fibromuscular Dysplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Sanofi Recent Developments and Future Plans
2.3 Bayer
2.3.1 Bayer Details
2.3.2 Bayer Major Business
2.3.3 Bayer Fibromuscular Dysplasia Treatment Product and Solutions
2.3.4 Bayer Fibromuscular Dysplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Bayer Recent Developments and Future Plans
2.4 Merck
2.4.1 Merck Details
2.4.2 Merck Major Business
2.4.3 Merck Fibromuscular Dysplasia Treatment Product and Solutions
2.4.4 Merck Fibromuscular Dysplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Merck Recent Developments and Future Plans
2.5 Novartis
2.5.1 Novartis Details
2.5.2 Novartis Major Business
2.5.3 Novartis Fibromuscular Dysplasia Treatment Product and Solutions
2.5.4 Novartis Fibromuscular Dysplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Novartis Recent Developments and Future Plans
2.6 Bristol-Myers Squibb
2.6.1 Bristol-Myers Squibb Details
2.6.2 Bristol-Myers Squibb Major Business
2.6.3 Bristol-Myers Squibb Fibromuscular Dysplasia Treatment Product and Solutions
2.6.4 Bristol-Myers Squibb Fibromuscular Dysplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.7 AstraZeneca
2.7.1 AstraZeneca Details
2.7.2 AstraZeneca Major Business
2.7.3 AstraZeneca Fibromuscular Dysplasia Treatment Product and Solutions
2.7.4 AstraZeneca Fibromuscular Dysplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 AstraZeneca Recent Developments and Future Plans
2.8 Allergan
2.8.1 Allergan Details
2.8.2 Allergan Major Business
2.8.3 Allergan Fibromuscular Dysplasia Treatment Product and Solutions
2.8.4 Allergan Fibromuscular Dysplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Allergan Recent Developments and Future Plans
2.9 Medtronic
2.9.1 Medtronic Details
2.9.2 Medtronic Major Business
2.9.3 Medtronic Fibromuscular Dysplasia Treatment Product and Solutions
2.9.4 Medtronic Fibromuscular Dysplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Medtronic Recent Developments and Future Plans
2.10 BD
2.10.1 BD Details
2.10.2 BD Major Business
2.10.3 BD Fibromuscular Dysplasia Treatment Product and Solutions
2.10.4 BD Fibromuscular Dysplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 BD Recent Developments and Future Plans
2.11 Smith & Nephew
2.11.1 Smith & Nephew Details
2.11.2 Smith & Nephew Major Business
2.11.3 Smith & Nephew Fibromuscular Dysplasia Treatment Product and Solutions
2.11.4 Smith & Nephew Fibromuscular Dysplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Smith & Nephew Recent Developments and Future Plans
2.12 Stryker
2.12.1 Stryker Details
2.12.2 Stryker Major Business
2.12.3 Stryker Fibromuscular Dysplasia Treatment Product and Solutions
2.12.4 Stryker Fibromuscular Dysplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Stryker Recent Developments and Future Plans
2.13 B. Braun Melsungen
2.13.1 B. Braun Melsungen Details
2.13.2 B. Braun Melsungen Major Business
2.13.3 B. Braun Melsungen Fibromuscular Dysplasia Treatment Product and Solutions
2.13.4 B. Braun Melsungen Fibromuscular Dysplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 B. Braun Melsungen Recent Developments and Future Plans
2.14 Johnson & Johnson
2.14.1 Johnson & Johnson Details
2.14.2 Johnson & Johnson Major Business
2.14.3 Johnson & Johnson Fibromuscular Dysplasia Treatment Product and Solutions
2.14.4 Johnson & Johnson Fibromuscular Dysplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 Johnson & Johnson Recent Developments and Future Plans
2.15 Hill-Rom
2.15.1 Hill-Rom Details
2.15.2 Hill-Rom Major Business
2.15.3 Hill-Rom Fibromuscular Dysplasia Treatment Product and Solutions
2.15.4 Hill-Rom Fibromuscular Dysplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.15.5 Hill-Rom Recent Developments and Future Plans
2.16 Alkermes Pharma Ireland
2.16.1 Alkermes Pharma Ireland Details
2.16.2 Alkermes Pharma Ireland Major Business
2.16.3 Alkermes Pharma Ireland Fibromuscular Dysplasia Treatment Product and Solutions
2.16.4 Alkermes Pharma Ireland Fibromuscular Dysplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.16.5 Alkermes Pharma Ireland Recent Developments and Future Plans
2.17 Dainippon Sumitomo Pharma
2.17.1 Dainippon Sumitomo Pharma Details
2.17.2 Dainippon Sumitomo Pharma Major Business
2.17.3 Dainippon Sumitomo Pharma Fibromuscular Dysplasia Treatment Product and Solutions
2.17.4 Dainippon Sumitomo Pharma Fibromuscular Dysplasia Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.17.5 Dainippon Sumitomo Pharma Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Fibromuscular Dysplasia Treatment Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Fibromuscular Dysplasia Treatment Players Market Share
3.2.2 Top 10 Fibromuscular Dysplasia Treatment Players Market Share
3.2.3 Market Competition Trend
3.3 Fibromuscular Dysplasia Treatment Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Fibromuscular Dysplasia Treatment Revenue and Market Share by Type (2016-2021)
4.2 Global Fibromuscular Dysplasia Treatment Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Fibromuscular Dysplasia Treatment Revenue Market Share by Application (2016-2021)
5.2 Fibromuscular Dysplasia Treatment Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Fibromuscular Dysplasia Treatment Revenue by Type (2016-2026)
6.2 North America Fibromuscular Dysplasia Treatment Revenue by Application (2016-2026)
6.3 North America Fibromuscular Dysplasia Treatment Market Size by Country
6.3.1 North America Fibromuscular Dysplasia Treatment Revenue by Country (2016-2026)
6.3.2 United States Fibromuscular Dysplasia Treatment Market Size and Forecast (2016-2026)
6.3.3 Canada Fibromuscular Dysplasia Treatment Market Size and Forecast (2016-2026)
6.3.4 Mexico Fibromuscular Dysplasia Treatment Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Fibromuscular Dysplasia Treatment Revenue by Type (2016-2026)
7.2 Europe Fibromuscular Dysplasia Treatment Revenue by Application (2016-2026)
7.3 Europe Fibromuscular Dysplasia Treatment Market Size by Country
7.3.1 Europe Fibromuscular Dysplasia Treatment Revenue by Country (2016-2026)
7.3.2 Germany Fibromuscular Dysplasia Treatment Market Size and Forecast (2016-2026)
7.3.3 France Fibromuscular Dysplasia Treatment Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Fibromuscular Dysplasia Treatment Market Size and Forecast (2016-2026)
7.3.5 Russia Fibromuscular Dysplasia Treatment Market Size and Forecast (2016-2026)
7.3.6 Italy Fibromuscular Dysplasia Treatment Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Fibromuscular Dysplasia Treatment Revenue by Type (2016-2026)
8.2 Asia-Pacific Fibromuscular Dysplasia Treatment Revenue by Application (2016-2026)
8.3 Asia-Pacific Fibromuscular Dysplasia Treatment Market Size by Region
8.3.1 Asia-Pacific Fibromuscular Dysplasia Treatment Revenue by Region (2016-2026)
8.3.2 China Fibromuscular Dysplasia Treatment Market Size and Forecast (2016-2026)
8.3.3 Japan Fibromuscular Dysplasia Treatment Market Size and Forecast (2016-2026)
8.3.4 South Korea Fibromuscular Dysplasia Treatment Market Size and Forecast (2016-2026)
8.3.5 India Fibromuscular Dysplasia Treatment Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Fibromuscular Dysplasia Treatment Market Size and Forecast (2016-2026)
8.3.7 Australia Fibromuscular Dysplasia Treatment Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Fibromuscular Dysplasia Treatment Revenue by Type (2016-2026)
9.2 South America Fibromuscular Dysplasia Treatment Revenue by Application (2016-2026)
9.3 South America Fibromuscular Dysplasia Treatment Market Size by Country
9.3.1 South America Fibromuscular Dysplasia Treatment Revenue by Country (2016-2026)
9.3.2 Brazil Fibromuscular Dysplasia Treatment Market Size and Forecast (2016-2026)
9.3.3 Argentina Fibromuscular Dysplasia Treatment Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Fibromuscular Dysplasia Treatment Revenue by Type (2016-2026)
10.2 Middle East & Africa Fibromuscular Dysplasia Treatment Revenue by Application (2016-2026)
10.3 Middle East & Africa Fibromuscular Dysplasia Treatment Market Size by Country
10.3.1 Middle East & Africa Fibromuscular Dysplasia Treatment Revenue by Country (2016-2026)
10.3.2 Turkey Fibromuscular Dysplasia Treatment Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Fibromuscular Dysplasia Treatment Market Size and Forecast (2016-2026)
10.3.4 UAE Fibromuscular Dysplasia Treatment Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Fibromuscular Dysplasia Treatment Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Fibromuscular Dysplasia Treatment Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Fibromuscular Dysplasia Treatment Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Fibromuscular Dysplasia Treatment Revenue (USD Million) by Region (2016-2021)
Table 5. Global Fibromuscular Dysplasia Treatment Revenue Market Share by Region (2021-2026)
Table 6. Pfizer Corporate Information, Head Office, and Major Competitors
Table 7. Pfizer Major Business
Table 8. Pfizer Fibromuscular Dysplasia Treatment Product and Solutions
Table 9. Pfizer Fibromuscular Dysplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Sanofi Corporate Information, Head Office, and Major Competitors
Table 11. Sanofi Major Business
Table 12. Sanofi Fibromuscular Dysplasia Treatment Product and Solutions
Table 13. Sanofi Fibromuscular Dysplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Bayer Corporate Information, Head Office, and Major Competitors
Table 15. Bayer Major Business
Table 16. Bayer Fibromuscular Dysplasia Treatment Product and Solutions
Table 17. Bayer Fibromuscular Dysplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Merck Corporate Information, Head Office, and Major Competitors
Table 19. Merck Major Business
Table 20. Merck Fibromuscular Dysplasia Treatment Product and Solutions
Table 21. Merck Fibromuscular Dysplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Novartis Corporate Information, Head Office, and Major Competitors
Table 23. Novartis Major Business
Table 24. Novartis Fibromuscular Dysplasia Treatment Product and Solutions
Table 25. Novartis Fibromuscular Dysplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors
Table 27. Bristol-Myers Squibb Major Business
Table 28. Bristol-Myers Squibb Fibromuscular Dysplasia Treatment Product and Solutions
Table 29. Bristol-Myers Squibb Fibromuscular Dysplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 31. AstraZeneca Major Business
Table 32. AstraZeneca Fibromuscular Dysplasia Treatment Product and Solutions
Table 33. AstraZeneca Fibromuscular Dysplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Allergan Corporate Information, Head Office, and Major Competitors
Table 35. Allergan Major Business
Table 36. Allergan Fibromuscular Dysplasia Treatment Product and Solutions
Table 37. Allergan Fibromuscular Dysplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Medtronic Corporate Information, Head Office, and Major Competitors
Table 39. Medtronic Major Business
Table 40. Medtronic Fibromuscular Dysplasia Treatment Product and Solutions
Table 41. Medtronic Fibromuscular Dysplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. BD Corporate Information, Head Office, and Major Competitors
Table 43. BD Major Business
Table 44. BD Fibromuscular Dysplasia Treatment Product and Solutions
Table 45. BD Fibromuscular Dysplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Smith & Nephew Corporate Information, Head Office, and Major Competitors
Table 47. Smith & Nephew Major Business
Table 48. Smith & Nephew Fibromuscular Dysplasia Treatment Product and Solutions
Table 49. Smith & Nephew Fibromuscular Dysplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Stryker Corporate Information, Head Office, and Major Competitors
Table 51. Stryker Major Business
Table 52. Stryker Fibromuscular Dysplasia Treatment Product and Solutions
Table 53. Stryker Fibromuscular Dysplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. B. Braun Melsungen Corporate Information, Head Office, and Major Competitors
Table 55. B. Braun Melsungen Major Business
Table 56. B. Braun Melsungen Fibromuscular Dysplasia Treatment Product and Solutions
Table 57. B. Braun Melsungen Fibromuscular Dysplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. Johnson & Johnson Corporate Information, Head Office, and Major Competitors
Table 59. Johnson & Johnson Major Business
Table 60. Johnson & Johnson Fibromuscular Dysplasia Treatment Product and Solutions
Table 61. Johnson & Johnson Fibromuscular Dysplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 62. Hill-Rom Corporate Information, Head Office, and Major Competitors
Table 63. Hill-Rom Major Business
Table 64. Hill-Rom Fibromuscular Dysplasia Treatment Product and Solutions
Table 65. Hill-Rom Fibromuscular Dysplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 66. Alkermes Pharma Ireland Corporate Information, Head Office, and Major Competitors
Table 67. Alkermes Pharma Ireland Major Business
Table 68. Alkermes Pharma Ireland Fibromuscular Dysplasia Treatment Product and Solutions
Table 69. Alkermes Pharma Ireland Fibromuscular Dysplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 70. Dainippon Sumitomo Pharma Corporate Information, Head Office, and Major Competitors
Table 71. Dainippon Sumitomo Pharma Major Business
Table 72. Dainippon Sumitomo Pharma Fibromuscular Dysplasia Treatment Product and Solutions
Table 73. Dainippon Sumitomo Pharma Fibromuscular Dysplasia Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 74. Global Fibromuscular Dysplasia Treatment Revenue (USD Million) by Players (2019-2021)
Table 75. Global Fibromuscular Dysplasia Treatment Revenue Share by Players (2019-2021)
Table 76. Breakdown of Fibromuscular Dysplasia Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 77. Fibromuscular Dysplasia Treatment Players Head Office, Products and Services Provided
Table 78. Fibromuscular Dysplasia Treatment Mergers & Acquisitions in the Past Five Years
Table 79. Fibromuscular Dysplasia Treatment New Entrants and Expansion Plans
Table 80. Global Fibromuscular Dysplasia Treatment Revenue (USD Million) by Type (2016-2021)
Table 81. Global Fibromuscular Dysplasia Treatment Revenue Share by Type (2016-2021)
Table 82. Global Fibromuscular Dysplasia Treatment Revenue Forecast by Type (2021-2026)
Table 83. Global Fibromuscular Dysplasia Treatment Revenue by Application (2016-2021)
Table 84. Global Fibromuscular Dysplasia Treatment Revenue Forecast by Application (2021-2026)
Table 85. North America Fibromuscular Dysplasia Treatment Revenue by Type (2016-2021) & (USD Million)
Table 86. North America Fibromuscular Dysplasia Treatment Revenue by Type (2021-2026) & (USD Million)
Table 87. North America Fibromuscular Dysplasia Treatment Revenue by Application (2016-2021) & (USD Million)
Table 88. North America Fibromuscular Dysplasia Treatment Revenue by Application (2021-2026) & (USD Million)
Table 89. North America Fibromuscular Dysplasia Treatment Revenue by Country (2016-2021) & (USD Million)
Table 90. North America Fibromuscular Dysplasia Treatment Revenue by Country (2021-2026) & (USD Million)
Table 91. Europe Fibromuscular Dysplasia Treatment Revenue by Type (2016-2021) & (USD Million)
Table 92. Europe Fibromuscular Dysplasia Treatment Revenue by Type (2021-2026) & (USD Million)
Table 93. Europe Fibromuscular Dysplasia Treatment Revenue by Application (2016-2021) & (USD Million)
Table 94. Europe Fibromuscular Dysplasia Treatment Revenue by Application (2021-2026) & (USD Million)
Table 95. Europe Fibromuscular Dysplasia Treatment Revenue by Country (2016-2021) & (USD Million)
Table 96. Europe Fibromuscular Dysplasia Treatment Revenue by Country (2021-2026) & (USD Million)
Table 97. Asia-Pacific Fibromuscular Dysplasia Treatment Revenue by Type (2016-2021) & (USD Million)
Table 98. Asia-Pacific Fibromuscular Dysplasia Treatment Revenue by Type (2021-2026) & (USD Million)
Table 99. Asia-Pacific Fibromuscular Dysplasia Treatment Revenue by Application (2016-2021) & (USD Million)
Table 100. Asia-Pacific Fibromuscular Dysplasia Treatment Revenue by Application (2021-2026) & (USD Million)
Table 101. Asia-Pacific Fibromuscular Dysplasia Treatment Revenue by Region (2016-2021) & (USD Million)
Table 102. Asia-Pacific Fibromuscular Dysplasia Treatment Revenue by Region (2021-2026) & (USD Million)
Table 103. South America Fibromuscular Dysplasia Treatment Revenue by Type (2016-2021) & (USD Million)
Table 104. South America Fibromuscular Dysplasia Treatment Revenue by Type (2021-2026) & (USD Million)
Table 105. South America Fibromuscular Dysplasia Treatment Revenue by Application (2016-2021) & (USD Million)
Table 106. South America Fibromuscular Dysplasia Treatment Revenue by Application (2021-2026) & (USD Million)
Table 107. South America Fibromuscular Dysplasia Treatment Revenue by Country (2016-2021) & (USD Million)
Table 108. South America Fibromuscular Dysplasia Treatment Revenue by Country (2021-2026) & (USD Million)
Table 109. Middle East & Africa Fibromuscular Dysplasia Treatment Revenue by Type (2016-2021) & (USD Million)
Table 110. Middle East & Africa Fibromuscular Dysplasia Treatment Revenue by Type (2021-2026) & (USD Million)
Table 111. Middle East & Africa Fibromuscular Dysplasia Treatment Revenue by Application (2016-2021) & (USD Million)
Table 112. Middle East & Africa Fibromuscular Dysplasia Treatment Revenue by Application (2021-2026) & (USD Million)
Table 113. Middle East & Africa Fibromuscular Dysplasia Treatment Revenue by Country (2016-2021) & (USD Million)
Table 114. Middle East & Africa Fibromuscular Dysplasia Treatment Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Fibromuscular Dysplasia Treatment Picture
Figure 2. Global Fibromuscular Dysplasia Treatment Revenue Market Share by Type in 2020
Figure 3. Surgery Therapy
Figure 4. Medication
Figure 5. Fibromuscular Dysplasia Treatment Revenue Market Share by Application in 2020
Figure 6. Hospitals Picture
Figure 7. Clinics Picture
Figure 8. Others Picture
Figure 9. Global Fibromuscular Dysplasia Treatment Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 10. Global Fibromuscular Dysplasia Treatment Revenue and Forecast (2016-2026) & (USD Million)
Figure 11. Global Fibromuscular Dysplasia Treatment Revenue Market Share by Region (2016-2026)
Figure 12. Global Fibromuscular Dysplasia Treatment Revenue Market Share by Region in 2020
Figure 13. North America Fibromuscular Dysplasia Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 14. Europe Fibromuscular Dysplasia Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Asia-Pacific Fibromuscular Dysplasia Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. South America Fibromuscular Dysplasia Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Middle East and Africa Fibromuscular Dysplasia Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Fibromuscular Dysplasia Treatment Market Drivers
Figure 19. Fibromuscular Dysplasia Treatment Market Restraints
Figure 20. Fibromuscular Dysplasia Treatment Market Trends
Figure 21. Pfizer Recent Developments and Future Plans
Figure 22. Sanofi Recent Developments and Future Plans
Figure 23. Bayer Recent Developments and Future Plans
Figure 24. Merck Recent Developments and Future Plans
Figure 25. Novartis Recent Developments and Future Plans
Figure 26. Bristol-Myers Squibb Recent Developments and Future Plans
Figure 27. AstraZeneca Recent Developments and Future Plans
Figure 28. Allergan Recent Developments and Future Plans
Figure 29. Medtronic Recent Developments and Future Plans
Figure 30. BD Recent Developments and Future Plans
Figure 31. Smith & Nephew Recent Developments and Future Plans
Figure 32. Stryker Recent Developments and Future Plans
Figure 33. B. Braun Melsungen Recent Developments and Future Plans
Figure 34. Johnson & Johnson Recent Developments and Future Plans
Figure 35. Hill-Rom Recent Developments and Future Plans
Figure 36. Alkermes Pharma Ireland Recent Developments and Future Plans
Figure 37. Dainippon Sumitomo Pharma Recent Developments and Future Plans
Figure 38. Global Fibromuscular Dysplasia Treatment Revenue Share by Players in 2020
Figure 39. Fibromuscular Dysplasia Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 40. Global Top 3 Players Fibromuscular Dysplasia Treatment Revenue Market Share in 2020
Figure 41. Global Top 10 Players Fibromuscular Dysplasia Treatment Revenue Market Share in 2020
Figure 42. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 43. Global Fibromuscular Dysplasia Treatment Revenue Share by Type in 2020
Figure 44. Global Fibromuscular Dysplasia Treatment Market Share Forecast by Type (2021-2026)
Figure 45. Global Fibromuscular Dysplasia Treatment Revenue Share by Application in 2020
Figure 46. Global Fibromuscular Dysplasia Treatment Market Share Forecast by Application (2021-2026)
Figure 47. North America Fibromuscular Dysplasia Treatment Sales Market Share by Type (2016-2026)
Figure 48. North America Fibromuscular Dysplasia Treatment Sales Market Share by Application (2016-2026)
Figure 49. North America Fibromuscular Dysplasia Treatment Revenue Market Share by Country (2016-2026)
Figure 50. United States Fibromuscular Dysplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Canada Fibromuscular Dysplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Mexico Fibromuscular Dysplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Europe Fibromuscular Dysplasia Treatment Sales Market Share by Type (2016-2026)
Figure 54. Europe Fibromuscular Dysplasia Treatment Sales Market Share by Application (2016-2026)
Figure 55. Europe Fibromuscular Dysplasia Treatment Revenue Market Share by Country (2016-2026)
Figure 56. Germany Fibromuscular Dysplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. France Fibromuscular Dysplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. United Kingdom Fibromuscular Dysplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Russia Fibromuscular Dysplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Italy Fibromuscular Dysplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Asia-Pacific Fibromuscular Dysplasia Treatment Sales Market Share by Type (2016-2026)
Figure 62. Asia-Pacific Fibromuscular Dysplasia Treatment Sales Market Share by Application (2016-2026)
Figure 63. Asia-Pacific Fibromuscular Dysplasia Treatment Revenue Market Share by Region (2016-2026)
Figure 64. China Fibromuscular Dysplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Japan Fibromuscular Dysplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. South Korea Fibromuscular Dysplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. India Fibromuscular Dysplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Southeast Asia Fibromuscular Dysplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Australia Fibromuscular Dysplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. South America Fibromuscular Dysplasia Treatment Sales Market Share by Type (2016-2026)
Figure 71. South America Fibromuscular Dysplasia Treatment Sales Market Share by Application (2016-2026)
Figure 72. South America Fibromuscular Dysplasia Treatment Revenue Market Share by Country (2016-2026)
Figure 73. Brazil Fibromuscular Dysplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 74. Argentina Fibromuscular Dysplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 75. Middle East and Africa Fibromuscular Dysplasia Treatment Sales Market Share by Type (2016-2026)
Figure 76. Middle East and Africa Fibromuscular Dysplasia Treatment Sales Market Share by Application (2016-2026)
Figure 77. Middle East and Africa Fibromuscular Dysplasia Treatment Revenue Market Share by Country (2016-2026)
Figure 78. Turkey Fibromuscular Dysplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. Saudi Arabia Fibromuscular Dysplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 80. UAE Fibromuscular Dysplasia Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 81. Methodology
Figure 82. Research Process and Data Source

以下、関連資料のご紹介

世界の線維筋形成異常治療市場予測（～2024年）

Global Fibromuscular Dysplasia Treatment Market 2019 by Company, Regions, Type and Application, Forecast to 2024
B-GIR09D3967 2019年9月18日 136Pages
本調査レポートは、線維筋形成異常治療の世界市場について調べ、まとめました。種類別セグメントは、手術療法、薬物療法等、用途別セグメントは、病院、診療所、その他等に区分しました。線維筋形成異常治療の世界市場概観、企業動向、企業別線維筋形成異常治療シェア、市場規模推移、市場規模予測（2019年-2024年...

世界の動物整形外科治療市場 2021：企業別、地域別、種類・用途別

Global Veterinary Orthopedic Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-107A11993 2021年7月 91Pages
当調査資料では、動物整形外科治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。動物整形外科治療の種類別市場規模（十字靭帯断裂、膝蓋骨脱臼、股関節形成不全、肘異形成、骨折、変形性関節症管理、その他）、用途別市場規模（犬、猫、その他）、地域別市場規模（北...

世界の多汗症治療市場 2021：企業別、地域別、種類・用途別

Global Hyperhidrosis Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-107A14030 2021年7月 103Pages
当調査資料では、多汗症治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。多汗症治療の種類別市場規模（腋窩多汗症、手掌多汗症、足底多汗症、その他）、用途別市場規模（病院、外来手術センター、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中...

世界のブルーリ潰瘍治療市場 2021：企業別、地域別、種類・用途別

Global Buruli Ulcer Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-107A12126 2021年7月 105Pages
当調査資料では、ブルーリ潰瘍治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。ブルーリ潰瘍治療の種類別市場規模（手術、薬物治療、その他）、用途別市場規模（病院、クリニック、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南...

世界の咽頭後膿瘍治療市場 2021：企業別、地域別、種類・用途別

Global Retropharyngeal Abscess Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-107A12668 2021年7月 109Pages
当調査資料では、咽頭後膿瘍治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。咽頭後膿瘍治療の種類別市場規模（抗生物質、鎮痛剤、外科的ドレナージ、その他）、用途別市場規模（病院、クリニック、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、...

世界の狂犬病治療市場 2021：企業別、地域別、種類・用途別

Global Rabies Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-107A12635 2021年7月 91Pages
当調査資料では、狂犬病治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。狂犬病治療の種類別市場規模（細胞培養ワクチン（CCV）、狂犬病免疫グロブリン（RIG）、神経組織ワクチン（NTV））、用途別市場規模（発症前予防、発症後予防）、地域別市場規模（北...

世界の鼻ポリープ治療市場 2021：企業別、地域別、種類・用途別

Global Nasal Polyps Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-107A14060 2021年7月 108Pages
当調査資料では、鼻ポリープ治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。鼻ポリープ治療の種類別市場規模（薬理学的療法、手術）、用途別市場規模（病院、外来手術センター、専門クリニック）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本...

世界の坐骨神経痛治療市場 2021：企業別、地域別、種類・用途別

Global Sciatica Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-107A12685 2021年7月 100Pages
当調査資料では、坐骨神経痛治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。坐骨神経痛治療の種類別市場規模（薬品、外科的治療）、用途別市場規模（病院、クリニック、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南...

世界の尋常性天疱瘡治療市場 2021：企業別、地域別、種類・用途別

Global Pemphigus Vulgaris Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-107A12562 2021年7月 104Pages
当調査資料では、尋常性天疱瘡治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。尋常性天疱瘡治療の種類別市場規模（経口、注射）、用途別市場規模（病院薬局、小売薬局、オンライン薬局）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南ア...

世界の神経性過食症治療市場 2021：企業別、地域別、種類・用途別

Global Bulimia Nervosa Treatment Market 2021 by Company, Regions, Type and Application, Forecast to 2026
GIR-107A12123 2021年7月 100Pages
当調査資料では、神経性過食症治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。神経性過食症治療の種類別市場規模（薬物治療、心理治療、栄養療法、その他）、用途別市場規模（病院、クリニック、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中...

世界の線維筋形成異常治療市場予測（～2024年） Fibromuscular dysplasia (FMD) is a disease that causes abnormal cell development in the artery wall, which results in narrowing, i.e., stenosis, and enlargement, i.e., aneurysm of the medium-sized arteries in the body. Scope of the Report: The global Fibromuscular Dysplasia Treatment market is value…
気管支肺異形成症市場：世界及び中国市場分析・予測（～2024年） Bronchopulmonary Dysplasia Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Bronchopulmonary Dysplasia industry with a focus on the Chinese market. The report provides key statistics on the market status of the Bronchopulmonary…
世界の動物整形外科治療市場 2021：企業別、地域別、種類・用途別 The Veterinary Orthopedic Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade…
世界のダンピング症候群治療市場 2021：企業別、地域別、種類・用途別 The Dumping Syndrome Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regu…
世界の脳性麻痺治療市場 2021：企業別、地域別、種類・用途別 The Cerebral Palsy Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regula…